Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure.

Cell stem cell Pub Date : 2024-04-04 Epub Date: 2024-03-07 DOI:10.1016/j.stem.2024.02.005
Xiang Yuan, Jingqi Wu, Zhen Sun, Jin Cen, Yajing Shu, Chenhua Wang, Hong Li, Dongni Lin, Kun Zhang, Baihua Wu, Anil Dhawan, Ludi Zhang, Lijian Hui
{"title":"Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure.","authors":"Xiang Yuan, Jingqi Wu, Zhen Sun, Jin Cen, Yajing Shu, Chenhua Wang, Hong Li, Dongni Lin, Kun Zhang, Baihua Wu, Anil Dhawan, Ludi Zhang, Lijian Hui","doi":"10.1016/j.stem.2024.02.005","DOIUrl":null,"url":null,"abstract":"<p><p>Alginate-encapsulated hepatocyte transplantation is a promising strategy to treat liver failure. However, its clinical application was impeded by the lack of primary human hepatocytes and difficulty in controlling their quality. We previously reported proliferating human hepatocytes (ProliHHs). Here, quality-controlled ProliHHs were produced in mass and engineered as liver organoids to improve their maturity. Encapsulated ProliHHs liver organoids (eLO) were intraperitoneally transplanted to treat liver failure animals. Notably, eLO treatment increased the survival of mice with post-hepatectomy liver failure (PHLF) and ameliorated hyperammonemia and hypoglycemia by providing liver functions. Additionally, eLO treatment protected the gut from PHLF-augmented permeability and normalized the increased serum endotoxin and inflammatory response, which facilitated liver regeneration. The therapeutic effect of eLO was additionally proved in acetaminophen-induced liver failure. Furthermore, we performed assessments of toxicity and biodistribution, demonstrating that eLO had no adverse effects on animals and remained non-tumorigenic.</p>","PeriodicalId":93928,"journal":{"name":"Cell stem cell","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell stem cell","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.stem.2024.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Alginate-encapsulated hepatocyte transplantation is a promising strategy to treat liver failure. However, its clinical application was impeded by the lack of primary human hepatocytes and difficulty in controlling their quality. We previously reported proliferating human hepatocytes (ProliHHs). Here, quality-controlled ProliHHs were produced in mass and engineered as liver organoids to improve their maturity. Encapsulated ProliHHs liver organoids (eLO) were intraperitoneally transplanted to treat liver failure animals. Notably, eLO treatment increased the survival of mice with post-hepatectomy liver failure (PHLF) and ameliorated hyperammonemia and hypoglycemia by providing liver functions. Additionally, eLO treatment protected the gut from PHLF-augmented permeability and normalized the increased serum endotoxin and inflammatory response, which facilitated liver regeneration. The therapeutic effect of eLO was additionally proved in acetaminophen-induced liver failure. Furthermore, we performed assessments of toxicity and biodistribution, demonstrating that eLO had no adverse effects on animals and remained non-tumorigenic.

Abstract Image

封装增殖人肝细胞器官组织治疗肝衰竭的临床前疗效和安全性。
藻酸盐包裹肝细胞移植是治疗肝功能衰竭的一种很有前景的策略。然而,由于缺乏原代人类肝细胞且难以控制其质量,其临床应用受到了阻碍。我们曾报道过增殖人肝细胞(ProliHHs)。在这里,我们批量生产了质量可控的 ProliHHs,并将其设计为肝脏器官组织,以提高其成熟度。将封装的ProliHHs肝脏器官组织(eLO)腹腔移植治疗肝衰竭动物。值得注意的是,eLO治疗提高了肝切除术后肝衰竭(PHLF)小鼠的存活率,并通过提供肝功能改善了高氨血症和低血糖症。此外,eLO 还能保护肠道免受 PHLF 导致的渗透性增强的影响,并使增加的血清内毒素和炎症反应恢复正常,从而促进肝脏再生。在对乙酰氨基酚诱导的肝衰竭中,eLO 的治疗效果也得到了证实。此外,我们还对毒性和生物分布进行了评估,结果表明 eLO 对动物没有不良影响,也不会致癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信